3lkq › Citations

Cross-reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses.

Gras S, Kedzierski L, Valkenburg SA, Laurie K, Liu YC, Denholm JT, Richards MJ, Rimmelzwaan GF, Kelso A, Doherty PC, Turner SJ, Rossjohn J, Kedzierska K
Proc Natl Acad Sci U S A 107 12599-604 (2010)
Related entries: 3lkn, 3lko, 3lkp, 3lkr, 3lks

Cited: 126 times
EuropePMC logo PMID: 20616031

Abstract

Preexisting T-cell immunity directed at conserved viral regions promotes enhanced recovery from influenza virus infections, with there being some evidence of cross-protection directed at variable peptides. Strikingly, many of the immunogenic peptides derived from the current pandemic A(H1N1)-2009 influenza virus are representative of the catastrophic 1918 "Spanish flu" rather than more recent "seasonal" strains. We present immunological and structural analyses of cross-reactive CD8(+) T-cell-mediated immunity directed at a variable (although highly cross-reactive) immunodominant NP(418-426) peptide that binds to a large B7 family (HLA-B*3501/03/0702) found throughout human populations. Memory CD8(+) T-cell specificity was probed for 12 different NP(418) mutants that emerged over the 9 decades between the 1918 and 2009 pandemics. Although there is evidence of substantial cross-reactivity among seasonal NP(418) mutants, current memory T-cell profiles show no preexisting immunity to the 2009-NP(418) variant or the 1918-NP(418) variant. Natural infection with the A(H1N1)-2009 virus, however, elicits CD8(+) T cells specific for the 2009-NP(418) and 1918-NP(418) epitopes. This analysis points to the potential importance of cross-reactive T-cell populations that cover the possible spectrum of T-cell variants and suggests that the identification of key residues/motifs that elicit cross-reactive T-cell sets could facilitate the evolution of immunization protocols that provide a measure of protection against unpredicted pandemic influenza viruses. Thus, it is worth exploring the potential of vaccines that incorporate peptide variants with a proven potential for broader immunogenicity, especially to those that are not recognized by the current memory T-cell pool generated by exposure to influenza variants that cause successive seasonal epidemics.

Articles - 3lkq mentioned but not cited (3)

  1. Cross-reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses. Gras S, Kedzierski L, Valkenburg SA, Laurie K, Liu YC, Denholm JT, Richards MJ, Rimmelzwaan GF, Kelso A, Doherty PC, Turner SJ, Rossjohn J, Kedzierska K. Proc Natl Acad Sci U S A 107 12599-12604 (2010)
  2. Peptide-dependent conformational fluctuation determines the stability of the human leukocyte antigen class I complex. Yanaka S, Ueno T, Shi Y, Qi J, Gao GF, Tsumoto K, Sugase K. J Biol Chem 289 24680-24690 (2014)
  3. Analysis of the different subpeptidomes presented by the HLA class I molecules of the B7 supertype. Tirado-Herranz A, Guasp P, Pastor-Moreno A, Area-Navarro M, Alvarez I. Cell Immunol 387 104707 (2023)


Reviews citing this publication (35)

  1. Evasion of influenza A viruses from innate and adaptive immune responses. van de Sandt CE, Kreijtz JH, Rimmelzwaan GF. Viruses 4 1438-1476 (2012)
  2. Two years after pandemic influenza A/2009/H1N1: what have we learned? Cheng VC, To KK, Tse H, Hung IF, Yuen KY. Clin Microbiol Rev 25 223-263 (2012)
  3. Back to the Future: Lessons Learned From the 1918 Influenza Pandemic. Short KR, Kedzierska K, van de Sandt CE. Front Cell Infect Microbiol 8 343 (2018)
  4. Balancing Immune Protection and Immune Pathology by CD8(+) T-Cell Responses to Influenza Infection. Duan S, Thomas PG. Front Immunol 7 25 (2016)
  5. Harnessing the Power of T Cells: The Promising Hope for a Universal Influenza Vaccine. Clemens EB, van de Sandt C, Wong SS, Wakim LM, Valkenburg SA. Vaccines (Basel) 6 E18 (2018)
  6. Human influenza viruses and CD8(+) T cell responses. Grant EJ, Quiñones-Parra SM, Clemens EB, Kedzierska K. Curr Opin Virol 16 132-142 (2016)
  7. Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. Hillaire ML, Osterhaus AD, Rimmelzwaan GF. J Biomed Biotechnol 2011 939860 (2011)
  8. Knowns and unknowns of influenza B viruses. Koutsakos M, Nguyen TH, Barclay WS, Kedzierska K. Future Microbiol 11 119-135 (2016)
  9. Cross-reactivity of T cells and its role in the immune system. Petrova G, Ferrante A, Gorski J. Crit Rev Immunol 32 349-372 (2012)
  10. Innate and adaptive T cells in influenza disease. Nüssing S, Sant S, Koutsakos M, Subbarao K, Nguyen THO, Kedzierska K. Front Med 12 34-47 (2018)
  11. Immunity to seasonal and pandemic influenza A viruses. Valkenburg SA, Rutigliano JA, Ellebedy AH, Doherty PC, Thomas PG, Kedzierska K. Microbes Infect 13 489-501 (2011)
  12. Seroprevalence to influenza A(H1N1) 2009 virus--where are we? Broberg E, Nicoll A, Amato-Gauci A. Clin Vaccine Immunol 18 1205-1212 (2011)
  13. Impact of Aging and Cytomegalovirus on Immunological Response to Influenza Vaccination and Infection. Merani S, Pawelec G, Kuchel GA, McElhaney JE. Front Immunol 8 784 (2017)
  14. Recalling the Future: Immunological Memory Toward Unpredictable Influenza Viruses. Auladell M, Jia X, Hensen L, Chua B, Fox A, Nguyen THO, Doherty PC, Kedzierska K. Front Immunol 10 1400 (2019)
  15. Universal immunity to influenza must outwit immune evasion. Quiñones-Parra S, Loh L, Brown LE, Kedzierska K, Valkenburg SA. Front Microbiol 5 285 (2014)
  16. Influenza vaccines: T-cell responses deserve more attention. Schotsaert M, Saelens X, Leroux-Roels G. Expert Rev Vaccines 11 949-962 (2012)
  17. The Quest for a Truly Universal Influenza Vaccine. Jang YH, Seong BL. Front Cell Infect Microbiol 9 344 (2019)
  18. Return of inactivated whole-virus vaccine for superior efficacy. Furuya Y. Immunol Cell Biol 90 571-578 (2012)
  19. Immune Responses to Avian Influenza Viruses. Koutsakos M, Kedzierska K, Subbarao K. J Immunol 202 382-391 (2019)
  20. Clinical Advances in Viral-Vectored Influenza Vaccines. Sebastian S, Lambe T. Vaccines (Basel) 6 E29 (2018)
  21. Clearance of influenza virus infections by T cells: risk of collateral damage? Hillaire ML, Rimmelzwaan GF, Kreijtz JH. Curr Opin Virol 3 430-437 (2013)
  22. Expansions of NK-like αβT cells with chronologic aging: novel lymphocyte effectors that compensate for functional deficits of conventional NK cells and T cells. Vallejo AN, Mueller RG, Hamel DL, Way A, Dvergsten JA, Griffin P, Newman AB. Ageing Res Rev 10 354-361 (2011)
  23. Influenza pandemic epidemiologic and virologic diversity: reminding ourselves of the possibilities. Kasowski EJ, Garten RJ, Bridges CB. Clin Infect Dis 52 Suppl 1 S44-9 (2011)
  24. Cross-protective immune responses elicited by live attenuated influenza vaccines. Jang YH, Seong BL. Yonsei Med J 54 271-282 (2013)
  25. Progress on adenovirus-vectored universal influenza vaccines. Xiang K, Ying G, Yan Z, Shanshan Y, Lei Z, Hongjun L, Maosheng S. Hum Vaccin Immunother 11 1209-1222 (2015)
  26. Host Immunological Factors Enhancing Mortality of Young Adults during the 1918 Influenza Pandemic. McAuley JL, Kedzierska K, Brown LE, Shanks GD. Front Immunol 6 419 (2015)
  27. Universal Influenza Vaccines: Progress in Achieving Broad Cross-Protection In Vivo. Epstein SL. Am J Epidemiol 187 2603-2614 (2018)
  28. The human side of influenza. Oshansky CM, Thomas PG. J Leukoc Biol 92 83-96 (2012)
  29. Considerations in the design of vaccines that induce CD8 T cell mediated immunity. Zaiss DM, Boog CJ, van Eden W, Sijts AJ. Vaccine 28 7716-7722 (2010)
  30. The ABC of Major Histocompatibility Complexes and T Cell Receptors in Health and Disease. Kedzierska K, Koutsakos M. Viral Immunol 33 160-178 (2020)
  31. Flu Universal Vaccines: New Tricks on an Old Virus. Du R, Cui Q, Rong L. Virol Sin 36 13-24 (2021)
  32. Quantifying T Cell Cross-Reactivity: Influenza and Coronaviruses. Gaevert JA, Luque Duque D, Lythe G, Molina-París C, Thomas PG. Viruses 13 1786 (2021)
  33. Bioengineered Bovine Papillomavirus L1 Protein Virus-like Particle (VLP) Vaccines for Enhanced Induction of CD8 T Cell Responses through Cross-Priming. Viscidi RP, Rowley T, Bossis I. Int J Mol Sci 24 9851 (2023)
  34. Influenza B: Prospects for the Development of Cross-Protective Vaccines. Tsybalova LM, Stepanova LA, Ramsay ES, Vasin AV. Viruses 14 1323 (2022)
  35. Understanding the Role of HLA Class I Molecules in the Immune Response to Influenza Infection and Rational Design of a Peptide-Based Vaccine. Muraduzzaman AKM, Illing PT, Mifsud NA, Purcell AW. Viruses 14 2578 (2022)

Articles citing this publication (88)

  1. Cellular immune correlates of protection against symptomatic pandemic influenza. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, Bean T, Barclay W, Deeks JJ, Lalvani A. Nat Med 19 1305-1312 (2013)
  2. Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19. Bacher P, Rosati E, Esser D, Martini GR, Saggau C, Schiminsky E, Dargvainiene J, Schröder I, Wieters I, Khodamoradi Y, Eberhardt F, Vehreschild MJGT, Neb H, Sonntagbauer M, Conrad C, Tran F, Rosenstiel P, Markewitz R, Wandinger KP, Augustin M, Rybniker J, Kochanek M, Leypoldt F, Cornely OA, Koehler P, Franke A, Scheffold A. Immunity 53 1258-1271.e5 (2020)
  3. Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Miller MS, Gardner TJ, Krammer F, Aguado LC, Tortorella D, Basler CF, Palese P. Sci Transl Med 5 198ra107 (2013)
  4. Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. Weinfurter JT, Brunner K, Capuano SV, Li C, Broman KW, Kawaoka Y, Friedrich TC. PLoS Pathog 7 e1002381 (2011)
  5. Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities. Quiñones-Parra S, Grant E, Loh L, Nguyen TH, Campbell KA, Tong SY, Miller A, Doherty PC, Vijaykrishna D, Rossjohn J, Gras S, Kedzierska K. Proc Natl Acad Sci U S A 111 1049-1054 (2014)
  6. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. Weiskopf D, Angelo MA, Bangs DJ, Sidney J, Paul S, Peters B, de Silva AD, Lindow JC, Diehl SA, Whitehead S, Durbin A, Kirkpatrick B, Sette A. J Virol 89 120-128 (2015)
  7. CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses. Lineburg KE, Grant EJ, Swaminathan S, Chatzileontiadou DSM, Szeto C, Sloane H, Panikkar A, Raju J, Crooks P, Rehan S, Nguyen AT, Lekieffre L, Neller MA, Tong ZWM, Jayasinghe D, Chew KY, Lobos CA, Halim H, Burrows JM, Riboldi-Tunnicliffe A, Chen W, D'Orsogna L, Khanna R, Short KR, Smith C, Gras S. Immunity 54 1055-1065.e5 (2021)
  8. Molecular basis for universal HLA-A*0201-restricted CD8+ T-cell immunity against influenza viruses. Valkenburg SA, Josephs TM, Clemens EB, Grant EJ, Nguyen TH, Wang GC, Price DA, Miller A, Tong SY, Thomas PG, Doherty PC, Rossjohn J, Gras S, Kedzierska K. Proc Natl Acad Sci U S A 113 4440-4445 (2016)
  9. Nucleoprotein of influenza A virus is a major target of immunodominant CD8+ T-cell responses. Grant E, Wu C, Chan KF, Eckle S, Bharadwaj M, Zou QM, Kedzierska K, Chen W. Immunol Cell Biol 91 184-194 (2013)
  10. Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens. Landry N, Pillet S, Favre D, Poulin JF, Trépanier S, Yassine-Diab B, Ward BJ. Clin Immunol 154 164-177 (2014)
  11. Early priming minimizes the age-related immune compromise of CD8⁺ T cell diversity and function. Valkenburg SA, Venturi V, Dang TH, Bird NL, Doherty PC, Turner SJ, Davenport MP, Kedzierska K. PLoS Pathog 8 e1002544 (2012)
  12. Human T-cells directed to seasonal influenza A virus cross-react with 2009 pandemic influenza A (H1N1) and swine-origin triple-reassortant H3N2 influenza viruses. Hillaire MLB, Vogelzang-van Trierum SE, Kreijtz JHCM, de Mutsert G, Fouchier RAM, Osterhaus ADME, Rimmelzwaan GF. J Gen Virol 94 583-592 (2013)
  13. Immunoinformatics Approach for Epitope-Based Peptide Vaccine Design and Active Site Prediction against Polyprotein of Emerging Oropouche Virus. Adhikari UK, Tayebi M, Rahman MM. J Immunol Res 2018 6718083 (2018)
  14. Single-Cell Approach to Influenza-Specific CD8+ T Cell Receptor Repertoires Across Different Age Groups, Tissues, and Following Influenza Virus Infection. Sant S, Grzelak L, Wang Z, Pizzolla A, Koutsakos M, Crowe J, Loudovaris T, Mannering SI, Westall GP, Wakim LM, Rossjohn J, Gras S, Richards M, Xu J, Thomas PG, Loh L, Nguyen THO, Kedzierska K. Front Immunol 9 1453 (2018)
  15. Narcolepsy-Associated HLA Class I Alleles Implicate Cell-Mediated Cytotoxicity. Tafti M, Lammers GJ, Dauvilliers Y, Overeem S, Mayer G, Nowak J, Pfister C, Dubois V, Eliaou JF, Eberhard HP, Liblau R, Wierzbicka A, Geisler P, Bassetti CL, Mathis J, Lecendreux M, Khatami R, Heinzer R, Haba-Rubio J, Feketeova E, Baumann CR, Kutalik Z, Tiercy JM. Sleep 39 581-587 (2016)
  16. Downregulation of MHC Class I Expression by Influenza A and B Viruses. Koutsakos M, McWilliam HEG, Aktepe TE, Fritzlar S, Illing PT, Mifsud NA, Purcell AW, Rockman S, Reading PC, Vivian JP, Rossjohn J, Brooks AG, Mackenzie JM, Mintern JD, Villadangos JA, Nguyen THO, Kedzierska K. Front Immunol 10 1158 (2019)
  17. HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection. Hertz T, Oshansky CM, Roddam PL, DeVincenzo JP, Caniza MA, Jojic N, Mallal S, Phillips E, James I, Halloran ME, Thomas PG, Corey L. Proc Natl Acad Sci U S A 110 13492-13497 (2013)
  18. Broad CD8+ T cell cross-recognition of distinct influenza A strains in humans. Grant EJ, Josephs TM, Loh L, Clemens EB, Sant S, Bharadwaj M, Chen W, Rossjohn J, Gras S, Kedzierska K. Nat Commun 9 5427 (2018)
  19. Epitope-based peptide vaccine design and target site depiction against Ebola viruses: an immunoinformatics study. Khan MA, Hossain MU, Rakib-Uz-Zaman SM, Morshed MN. Scand J Immunol 82 25-34 (2015)
  20. Humoral and cell-mediated immunity to pandemic H1N1 influenza in a Canadian cohort one year post-pandemic: implications for vaccination. Wagar LE, Rosella L, Crowcroft N, Lowcock B, Drohomyrecky PC, Foisy J, Gubbay J, Rebbapragada A, Winter AL, Achonu C, Ward BJ, Watts TH. PLoS One 6 e28063 (2011)
  21. Cross-allele cytotoxic T lymphocyte responses against 2009 pandemic H1N1 influenza A virus among HLA-A24 and HLA-A3 supertype-positive individuals. Liu J, Zhang S, Tan S, Yi Y, Wu B, Cao B, Zhu F, Wang C, Wang H, Qi J, Gao GF. J Virol 86 13281-13294 (2012)
  22. Conserved epitopes dominate cross-CD8+ T-cell responses against influenza A H1N1 virus among Asian populations. Liu J, Wu B, Zhang S, Tan S, Sun Y, Chen Z, Qin Y, Sun M, Shi G, Wu Y, Sun M, Liu N, Ning K, Ma Y, Gao B, Yan J, Zhu F, Wang H, Gao GF. Eur J Immunol 43 2055-2069 (2013)
  23. Epitope specific T-cell responses against influenza A in a healthy population. Savic M, Dembinski JL, Kim Y, Tunheim G, Cox RJ, Oftung F, Peters B, Mjaaland S. Immunology 147 165-177 (2016)
  24. Vaccine-associated enhanced respiratory disease is influenced by haemagglutinin and neuraminidase in whole inactivated influenza virus vaccines. Rajão DS, Chen H, Perez DR, Sandbulte MR, Gauger PC, Loving CL, Shanks GD, Vincent A. J Gen Virol 97 1489-1499 (2016)
  25. Engineering temperature sensitive live attenuated influenza vaccines from emerging viruses. Zhou B, Li Y, Speer SD, Subba A, Lin X, Wentworth DE. Vaccine 30 3691-3702 (2012)
  26. Towards identification of immune and genetic correlates of severe influenza disease in Indigenous Australians. Clemens EB, Grant EJ, Wang Z, Gras S, Tipping P, Rossjohn J, Miller A, Tong SY, Kedzierska K. Immunol Cell Biol 94 367-377 (2016)
  27. T-cell-mediated cross-strain protective immunity elicited by prime-boost vaccination with a live attenuated influenza vaccine. Li J, Arévalo MT, Chen Y, Chen S, Zeng M. Int J Infect Dis 27 37-43 (2014)
  28. Use it or lose it: establishment and persistence of T cell memory. Kedzierska K, Valkenburg SA, Doherty PC, Davenport MP, Venturi V. Front Immunol 3 357 (2012)
  29. A computational assay to design an epitope-based Peptide vaccine against saint louis encephalitis virus. Hasan MA, Hossain M, Alam MJ. Bioinform Biol Insights 7 347-355 (2013)
  30. Influenza-specific T cells from older people are enriched in the late effector subset and their presence inversely correlates with vaccine response. Wagar LE, Gentleman B, Pircher H, McElhaney JE, Watts TH. PLoS One 6 e23698 (2011)
  31. Previously Hidden Dynamics at the TCR-Peptide-MHC Interface Revealed. Fodor J, Riley BT, Borg NA, Buckle AM. J Immunol 200 4134-4145 (2018)
  32. A comprehensive immunoinformatics and target site study revealed the corner-stone toward Chikungunya virus treatment. Hasan MA, Khan MA, Datta A, Mazumder MH, Hossain MU. Mol Immunol 65 189-204 (2015)
  33. Indoleamine 2,3-dioxygenase (IDO) activity during the primary immune response to influenza infection modifies the memory T cell response to influenza challenge. Sage LK, Fox JM, Mellor AL, Tompkins SM, Tripp RA. Viral Immunol 27 112-123 (2014)
  34. Oseltamivir Prophylaxis Reduces Inflammation and Facilitates Establishment of Cross-Strain Protective T Cell Memory to Influenza Viruses. Bird NL, Olson MR, Hurt AC, Oshansky CM, Oh DY, Reading PC, Chua BY, Sun Y, Tang L, Handel A, Jackson DC, Turner SJ, Thomas PG, Kedzierska K. PLoS One 10 e0129768 (2015)
  35. The immunodominant influenza A virus M158-66 cytotoxic T lymphocyte epitope exhibits degenerate class I major histocompatibility complex restriction in humans. Choo JA, Liu J, Toh X, Grotenbreg GM, Ren EC. J Virol 88 10613-10623 (2014)
  36. Heterosubtypic Protections against Human-Infecting Avian Influenza Viruses Correlate to Biased Cross-T-Cell Responses. Zhao M, Liu K, Luo J, Tan S, Quan C, Zhang S, Chai Y, Qi J, Li Y, Bi Y, Xiao H, Wong G, Zhou J, Jiang T, Liu W, Yu H, Yan J, Liu Y, Shu Y, Wu G, Wu A, Gao GF, Liu WJ. mBio 9 e01408-18 (2018)
  37. Severity of influenza A 2009 (H1N1) pneumonia is underestimated by routine prediction rules. Results from a prospective, population-based study. Bjarnason A, Thorleifsdottir G, Löve A, Gudnason JF, Asgeirsson H, Hallgrimsson KL, Kristjansdottir BS, Haraldsson G, Baldursson O, Kristinsson KG, Gottfredsson M. PLoS One 7 e46816 (2012)
  38. Cross-immunity Against Avian Influenza A(H7N9) Virus in the Healthy Population Is Affected by Antigenicity-Dependent Substitutions. Liu WJ, Tan S, Zhao M, Quan C, Bi Y, Wu Y, Zhang S, Zhang H, Xiao H, Qi J, Yan J, Liu W, Yu H, Shu Y, Wu G, Gao GF. J Infect Dis 214 1937-1946 (2016)
  39. Maintenance of the EBV-specific CD8+ TCRαβ repertoire in immunosuppressed lung transplant recipients. Nguyen TH, Bird NL, Grant EJ, Miles JJ, Thomas PG, Kotsimbos TC, Mifsud NA, Kedzierska K. Immunol Cell Biol 95 77-86 (2017)
  40. Preemptive priming readily overcomes structure-based mechanisms of virus escape. Valkenburg SA, Gras S, Guillonneau C, Hatton LA, Bird NA, Twist KA, Halim H, Jackson DC, Purcell AW, Turner SJ, Doherty PC, Rossjohn J, Kedzierska K. Proc Natl Acad Sci U S A 110 5570-5575 (2013)
  41. A Role of Influenza Virus Exposure History in Determining Pandemic Susceptibility and CD8+ T Cell Responses. Quiñones-Parra SM, Clemens EB, Wang Z, Croom HA, Kedzierski L, McVernon J, Vijaykrishna D, Kedzierska K. J Virol 90 6936-6947 (2016)
  42. Diverse heterologous primary infections radically alter immunodominance hierarchies and clinical outcomes following H7N9 influenza challenge in mice. Duan S, Meliopoulos VA, McClaren JL, Guo XZ, Sanders CJ, Smallwood HS, Webby RJ, Schultz-Cherry SL, Doherty PC, Thomas PG. PLoS Pathog 11 e1004642 (2015)
  43. Lack of Heterologous Cross-reactivity toward HLA-A*02:01 Restricted Viral Epitopes Is Underpinned by Distinct αβT Cell Receptor Signatures. Grant EJ, Josephs TM, Valkenburg SA, Wooldridge L, Hellard M, Rossjohn J, Bharadwaj M, Kedzierska K, Gras S. J Biol Chem 291 24335-24351 (2016)
  44. Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice. Joe PT, Christopoulou I, van Hoecke L, Schepens B, Ysenbaert T, Heirman C, Thielemans K, Saelens X, Aerts JL. J Transl Med 17 242 (2019)
  45. Co-expression of HLA-B7 and HLA-B27 alleles is associated with B7-restricted immunodominant responses following influenza infection. Akram A, Inman RD. Eur J Immunol 43 3254-3267 (2013)
  46. Distinct T and NK cell populations may serve as immune correlates of protection against symptomatic pandemic influenza A(H1N1) virus infection during pregnancy. Savic M, Dembinski JL, Laake I, Hungnes O, Cox R, Oftung F, Trogstad L, Mjaaland S. PLoS One 12 e0188055 (2017)
  47. Highly conserved antigenic epitope regions of hemagglutinin and neuraminidase genes between 2009 H1N1 and seasonal H1N1 influenza: vaccine considerations. Huang P, Yu S, Wu C, Liang L. J Transl Med 11 47 (2013)
  48. Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity. Lehmann AA, Kirchenbaum GA, Zhang T, Reche PA, Lehmann PV. Front Immunol 12 635942 (2021)
  49. Eomes broadens the scope of CD8 T-cell memory by inhibiting apoptosis in cells of low affinity. Kavazović I, Han H, Balzaretti G, Slinger E, Lemmermann NAW, Ten Brinke A, Merkler D, Koster J, Bryceson YT, de Vries N, Jonjić S, Klarenbeek PL, Polić B, Eldering E, Wensveen FM. PLoS Biol 18 e3000648 (2020)
  50. Prior population immunity reduces the expected impact of CTL-inducing vaccines for pandemic influenza control. Bolton KJ, McCaw JM, Brown L, Jackson D, Kedzierska K, McVernon J. PLoS One 10 e0120138 (2015)
  51. The tetramer transformation. Doherty PC. J Immunol 187 5-6 (2011)
  52. Hemagglutinin-specific CD4+ T-cell responses following 2009-pH1N1 inactivated split-vaccine inoculation in humans. Tan S, Zhang S, Wu B, Zhao Y, Zhang W, Han M, Wu Y, Shi G, Liu Y, Yan J, Wu G, Wang H, Gao GF, Zhu F, Liu WJ. Vaccine 35 5644-5652 (2017)
  53. Potential T cell epitopes within swine-origin triple reassortant influenza A (H3N2) variant virus which emerged in 2011: an immunoinformatics study. Duvvuri VR, Marchand-Austin A, Eshaghi A, Patel SN, Low DE, Gubbay JB. Vaccine 30 6054-6063 (2012)
  54. A heat-inactivated H7N3 vaccine induces cross-reactive cellular immunity in HLA-A2.1 transgenic mice. Di Mario G, Garulli B, Sciaraffia E, Facchini M, Donatelli I, Castrucci MR. Virol J 13 56 (2016)
  55. Challenging immunodominance of influenza-specific CD8+ T cell responses restricted by the risk-associated HLA-A*68:01 allomorph. van de Sandt CE, Clemens EB, Grant EJ, Rowntree LC, Sant S, Halim H, Crowe J, Cheng AC, Kotsimbos TC, Richards M, Miller A, Tong SYC, Rossjohn J, Nguyen THO, Gras S, Chen W, Kedzierska K. Nat Commun 10 5579 (2019)
  56. Comparison of influenza and SIV specific CD8 T cell responses in macaques. Jegaskanda S, Reece JC, De Rose R, Stambas J, Sullivan L, Brooks AG, Kent SJ, Sexton A. PLoS One 7 e32431 (2012)
  57. Consequences of suboptimal priming are apparent for low-avidity T-cell responses. Venturi V, Davenport MP, Swan NG, Doherty PC, Kedzierska K. Immunol Cell Biol 90 216-223 (2012)
  58. Pan-Influenza A Protection by Prime-Boost Vaccination with Cold-Adapted Live-Attenuated Influenza Vaccine in a Mouse Model. Jang YH, Kim JY, Byun YH, Son A, Lee JY, Lee YJ, Chang J, Seong BL. Front Immunol 9 116 (2018)
  59. Characterization of Antigenic MHC-Class-I-Restricted T Cell Epitopes in the Glycoprotein of Ebolavirus. Powlson J, Wright D, Zeltina A, Giza M, Nielsen M, Rampling T, Venkatrakaman N, Bowden TA, Hill AVS, Ewer KJ. Cell Rep 29 2537-2545.e3 (2019)
  60. Diminished effector and memory CD8+ circulating T lymphocytes in patients with severe influenza caused by the AH1N1 pdm09 virus. Gonzalez Y, Juárez E, Carranza C, Sada E, Pedraza-Sánchez S, Torres M. Virology 500 139-148 (2017)
  61. Inability To Detect Cross-Reactive Memory T Cells Challenges the Frequency of Heterologous Immunity among Common Viruses. Rowntree LC, Nguyen THO, Halim H, Purcell AW, Rossjohn J, Gras S, Kotsimbos TC, Mifsud NA. J Immunol 200 3993-4003 (2018)
  62. Molecular docking analysis of 2009-H1N1 and 2004-H5N1 influenza virus HLA-B*4405-restricted HA epitope candidates: implications for TCR cross-recognition and vaccine development. Su CT, Schönbach C, Kwoh CK. BMC Bioinformatics 14 Suppl 2 S21 (2013)
  63. Computational perspectives revealed prospective vaccine candidates from five structural proteins of novel SARS corona virus 2019 (SARS-CoV-2). Anand R, Biswal S, Bhatt R, Tiwary BN. PeerJ 8 e9855 (2020)
  64. Evolution of viral life-cycle in response to cytotoxic T lymphocyte-mediated immunity. Louzoun Y, Ganusov VV. J Theor Biol 310 3-13 (2012)
  65. Live Attenuated Influenza Vaccines engineered to express the nucleoprotein of a recent isolate stimulate human influenza CD8+ T cells more relevant to current infections. Korenkov D, Nguyen THO, Isakova-Sivak I, Smolonogina T, Brown LE, Kedzierska K, Rudenko L. Hum Vaccin Immunother 14 941-946 (2018)
  66. Grouping of large populations into few CTL immune 'response-types' from influenza H1N1 genome analysis. Mukherjee S, Chandra N. Clin Transl Immunology 3 e24 (2014)
  67. HLA-B*27:05 alters immunodominance hierarchy of universal influenza-specific CD8+ T cells. Sant S, Quiñones-Parra SM, Koutsakos M, Grant EJ, Loudovaris T, Mannering SI, Crowe J, van de Sandt CE, Rimmelzwaan GF, Rossjohn J, Gras S, Loh L, Nguyen THO, Kedzierska K. PLoS Pathog 16 e1008714 (2020)
  68. Influenza Virus: A Brief Overview. Dangi T, Jain A. Proc Natl Acad Sci India Sect B Biol Sci 82 111-121 (2012)
  69. Investigation of CD4 and CD8 T cell-mediated protection against influenza A virus in a cohort study. Tsang TK, Lam KT, Liu Y, Fang VJ, Mu X, Leung NHL, Peiris JSM, Leung GM, Cowling BJ, Tu W. BMC Med 20 230 (2022)
  70. Predictive in silico binding algorithms reveal HLA specificities and autoallergen peptides associated with atopic dermatitis. Gong JJ, Margolis DJ, Monos DS. Arch Dermatol Res 312 647-656 (2020)
  71. Surveillance Study of Influenza Occurrence and Immunity in a Wisconsin Cohort During the 2009 Pandemic. Lo CY, Strobl SL, Dunham K, Wang W, Stewart L, Misplon JA, Garcia M, Gao J, Ozawa T, Price GE, Navidad J, Gradus S, Bhattacharyya S, Viboud C, Eichelberger MC, Weiss CD, Gorski J, Epstein SL. Open Forum Infect Dis 4 ofx023 (2017)
  72. Comment T-cell immune responses and asymptomatic H5N1 influenza infection. Epstein S. J Infect Dis 205 4-6 (2012)
  73. Identification of putative unique immunogenic ZIKV and DENV1-4 peptides for diagnostic cellular based tests. Oom AL, Smith D, Akrami K. Sci Rep 7 6218 (2017)
  74. Lineage-specific epitope profiles for HPAI H5 pre-pandemic vaccine selection and evaluation. Qiu X, Duvvuri VR, Gubbay JB, Webby RJ, Kayali G, Bahl J. Influenza Other Respir Viruses 11 445-456 (2017)
  75. Multi-task learning sparse group lasso: a method for quantifying antigenicity of influenza A(H1N1) virus using mutations and variations in glycosylation of Hemagglutinin. Li L, Chang D, Han L, Zhang X, Zaia J, Wan XF. BMC Bioinformatics 21 182 (2020)
  76. Prediction of peptide binding to a major histocompatibility complex class I molecule based on docking simulation. Ishikawa T. J Comput Aided Mol Des 30 875-887 (2016)
  77. Q&A: H1N1 pandemic influenza--what's new? Turner SJ, Doherty PC, Kelso A. BMC Biol 8 130 (2010)
  78. Subsisting H1N1 influenza memory responses are insufficient to protect from pandemic H1N1 influenza challenge in C57BL/6 mice. Sage LK, Fox JM, Tompkins SM, Tripp RA. J Gen Virol 94 1701-1711 (2013)
  79. A Novel Method Linking Antigen Presentation by Human Monocyte-Derived Macrophages to CD8(+) T Cell Polyfunctionality. Short KR, Grant EJ, Vissers M, Reading PC, Diavatopoulos DA, Kedzierska K. Front Immunol 4 389 (2013)
  80. In vitro modeling of the interaction between human epithelial cells and lymphocytes upon influenza infection. Ilyushina NA, Wright PF. Influenza Other Respir Viruses 10 438-442 (2016)
  81. Route of self-amplifying mRNA vaccination modulates the establishment of pulmonary resident memory CD8 and CD4 T cells. Künzli M, O'Flanagan SD, LaRue M, Talukder P, Dileepan T, Stolley JM, Soerens AG, Quarnstrom CF, Wijeyesinghe S, Ye Y, McPartlan JS, Mitchell JS, Mandl CW, Vile R, Jenkins MK, Ahmed R, Vezys V, Chahal JS, Masopust D. Sci Immunol 7 eadd3075 (2022)
  82. Study on age-dependent pre-existing 2009 pandemic influenza virus T and B cell responses from Chinese population. Lv J, Ren ZY, Zhang YY, Liu YE, Gao J, Yao K, Feng D, Li ZY, Feng X, Liu YX, Jia N. BMC Infect Dis 17 136 (2017)
  83. The 'Influenza' Vaccine Used during the Samoan Pandemic of 1918. Shanks GD. Trop Med Infect Dis 3 E17 (2018)
  84. Letter The evolution of HLA-B*3501 binding affinity to variable immunodominant NP(418-426) peptides from 1918 to 2009 pandemic influenza A virus: a molecular dynamics simulation and free energy calculation study. Guo J, Wang X, Sun H, Liu H, Shen Y, Yao X. Chem Biol Drug Des 79 1025-1032 (2012)
  85. Congress 4th Australasian vaccines and immunotherapeutic development meeting. Engwerda C, Belz G. Immunol Cell Biol 90 921-924 (2012)
  86. Characterization of the Efficacy of a Split Swine Influenza A Virus Nasal Vaccine Formulated with a Nanoparticle/STING Agonist Combination Adjuvant in Conventional Pigs. Patil V, Hernandez-Franco JF, Yadagiri G, Bugybayeva D, Dolatyabi S, Feliciano-Ruiz N, Schrock J, Suresh R, Hanson J, Yassine H, HogenEsch H, Renukaradhya GJ. Vaccines (Basel) 11 1707 (2023)
  87. Homologous peptides derived from influenza A, B and C viruses induce variable CD8+ T cell responses with cross-reactive potential. Nguyen AT, Lau HMP, Sloane H, Jayasinghe D, Mifsud NA, Chatzileontiadou DS, Grant EJ, Szeto C, Gras S. Clin Transl Immunology 11 e1422 (2022)
  88. Increasing HbA1c is associated with reduced CD8+ T cell functionality in response to influenza virus in a TCR-dependent manner in individuals with diabetes mellitus. Hulme KD, Tong ZWM, Rowntree LC, van de Sandt CE, Ronacher K, Grant EJ, Dorey ES, Gallo LA, Gras S, Kedzierska K, Barrett HL, Short KR. Cell Mol Life Sci 81 35 (2024)


Quick links